Lormed

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lormed

Property Description
Active ingredient Meloxicam (Prescription-only)
Form Tablet, capsule, oral suspension, IV solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose Relief of chronic pain and inflammation
Origin Synthetic oxicam derivative

Lormed is a prescription-only medication whose active component is meloxicam, definitively classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and widely used to address symptoms of chronic inflammation and persistent pain. The drug entity is a synthetic compound manufactured as an oxicam derivative, specifically belonging to the enolic acid group of anti-inflammatory agents.

The Core Identity and Differentiation

Lormed is primarily categorized as an NSAID, which establishes its therapeutic function as both a non-opioid analgesic and an active anti-inflammatory agent. A distinctive feature of its active component, meloxicam, is its relatively long half-life (approximately 20 hours), a property that is clinically recognized for supporting once-daily dosing, making it particularly suitable for the management of chronic conditions rather than acute discomfort. This long duration of action is a differentiating factor when compared to many shorter-acting members of the NSAID class.

Composition and Functional Type

Lormed is supplied as a single-ingredient product or monotherapy, where the composition includes only meloxicam alongside the necessary excipients for its specific delivery form. It is manufactured in several dosage forms, including conventional tablets, capsules, and an oral suspension for the oral route of administration, and specialized forms like the solution for intravenous administration (IV solution). Meloxicam's fundamental mechanism of effect is based on its identification as a preferential Cyclo-oxygenase-2 (COX-2) inhibitor, which modulates the enzyme primarily responsible for synthesizing prostaglandins—chemical messengers that mediate the symptoms of swelling and pain—thereby delivering its desired anti-inflammatory effect and analgesic effect.

Regulatory References

  1. MedlinePlus Drug Information on Meloxicam
  2. Meloxicam on NIH LiverTox

What side effects are possible with Lormed?

Possible Side Effects and Safety Information

Adverse reactions documented for Lormed (meloxicam) are structured by frequency and the body system affected, based on official regulatory classifications.

Adverse Reaction Scope

Category Regulatory Summary
Frequency classification Very Common reactions (affecting more than 1 in 10 patients) typically involve the gastrointestinal system. Common effects include headache, dizziness, and peripheral edema. Rare effects include gastrointestinal perforation, hepatitis, and serious skin reactions.
System-organ classes The most affected systems are Gastrointestinal Disorders, followed by Nervous System Disorders, Blood and Lymphatic System Disorders (e.g., anemia), and Renal and Urinary Disorders.
Serious adverse reactions Official documents carry explicit warnings about the risk of serious, potentially fatal, Cardiovascular Thrombotic Events (such as myocardial infarction and stroke) and severe Gastrointestinal Events (including bleeding, ulceration, and perforation).

Key Safety Considerations

  • Duration and Exposure: The risk of serious cardiovascular and gastrointestinal events may increase with the duration of use. Serious GI events can occur at any time, often without warning symptoms.
  • Population-Specific Risk: Older adults are at a greater documented risk for serious GI and CV adverse events. Patients with pre-existing renal or hepatic impairment require particular caution and monitoring as defined in the regulatory label.
  • Restrictions and Contraindications: Lormed is contraindicated for the treatment of pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery. It must not be used in individuals with a known history of hypersensitivity to aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Connection to the Overall Safety Profile

This official safety information establishes the boundaries of the drug’s risk profile by detailing both common, expected adverse reactions and the specific, potentially life-threatening serious events. The structured warnings emphasize that while the medicine is used for chronic conditions, its use is associated with duration-related risks, necessitating caution and monitoring for specific organ systems and vulnerable patient populations.

Overdose and Emergency Response

In cases of overdose with Lormed (meloxicam), documented presentations in regulatory labeling range from typically reversible effects to severe, life-threatening complications. Initial signs may include general symptoms such as nausea, vomiting, epigastric pain, lethargy, and drowsiness.

However, a substantial overdose can lead to more critical systemic issues. Officially recognized severe outcomes include gastrointestinal bleeding, acute renal failure, hepatic dysfunction, hypertension, and respiratory depression. The most severe outcomes, as noted in regulatory documents, encompass cardiovascular collapse, cardiac arrest, convulsions, and coma. Patients with underlying renal or hepatic impairment may face an increased risk of severe adverse outcomes following an overdose.

Official guidance mandates that you seek medical attention immediately if an overdose is suspected. Urgent contact with emergency services is required if the person experiences a seizure, is unresponsive, or has difficulty breathing.

Management relies on symptomatic and supportive care, as no specific antidote is known for meloxicam. For a substantial acute overdose, interventions such as the administration of activated charcoal are procedures listed in the official prescribing information, alongside the use of agents like Cholestyramine, which is known to accelerate the drug’s clearance.

Therapeutic Uses of Lormed

What Lormed Treats: Main Uses and Benefits

Lormed (meloxicam) is a prescription medication commonly used in the symptomatic management of conditions marked by persistent pain and symptoms related to inflammatory or irritative states. It is relevant for easing symptoms associated with major chronic arthritic conditions.

The medication primarily helps address symptom clusters related to physical discomfort in the joints and skeletal system. It is commonly used in conditions such as Osteoarthritis, Rheumatoid Arthritis (RA) in adults, Ankylosing Spondylitis, and Juvenile Idiopathic Arthritis (JIA) in children aged two years and older. In these contexts, Lormed provides supportive relief when symptoms interfere with routine daily activities, such as persistent joint pain, swelling, tenderness, or stiffness.

Lormed is also utilized in specific clinical settings, such as postsurgical analgesia, for the management of moderate-to-severe pain. This use provides support that helps ease the overall symptom burden during phases of increased distress or discomfort, assisting with maintaining functional stability during recovery.

Quick Fact: Symptomatic Support for Chronic Joint Discomfort

Lormed is generally applied when additional symptomatic support is needed, assisting with the management of challenging manifestations during symptomatic phases of chronic conditions.

Regulatory References

  1. FDA DailyMed Label for Meloxicam

Eligibility and Restrictions for Use

Who Can and Cannot Use Lormed?

This section summarizes the official population eligibility rules for Lormed (meloxicam) as strictly defined in government regulatory documents.

Eligibility Status

Status Population/Condition
Allowed Use Adult patients with Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis. Pediatric patients 2 years for Juvenile Idiopathic Arthritis only.
Contraindicated Known hypersensitivity to meloxicam or any NSAID (including aspirin-sensitive asthma). Peri-operative pain management for Coronary Artery Bypass Graft (CABG) surgery.

Official Exclusions and Restrictions

Absolute Prohibition: The medicine is strictly contraindicated in patients with active gastrointestinal bleeding or ulceration, severe uncontrolled heart failure, severe non-dialyzed renal impairment (CrCl <30 mL/min), or severe uncompensated hepatic impairment.

Age and Reproductive Restrictions: Use must be avoided in pregnant individuals starting at 20 weeks gestation and later. It is not recommended while breastfeeding. The medicine is not established for use in children under 2 years of age. Older adult (geriatric) patients are an eligible group but regulatory documentation requires the use of caution and monitoring.

What should I know about interactions with other medicines?

The official interaction profile for Lormed (meloxicam) is structured around pharmacodynamic and pharmacokinetic patterns documented in regulatory information.

Documented Interaction Patterns

Contraindicated Combinations

  • Other NSAIDs: Co-administration with other Nonsteroidal Anti-inflammatory Drugs, including other selective COX-2 inhibitors, is formally contraindicated due to the synergistic risk of severe gastrointestinal ulceration and bleeding.
  • Aspirin: The combination is generally contraindicated when aspirin is administered at analgesic or anti-inflammatory doses.

Exposure-Altering Interactions

Co-administration with inhibitors of the metabolic enzymes CYP2C9 and CYP3A4 is documented to significantly increase the systemic exposure (AUC and Cmax) of Lormed. Conversely, Cholestyramine is noted to increase the clearance and elimination of Lormed.

Pharmacodynamic Risk Enhancement

  • Anticoagulants and Antiplatelet Agents: Co-administration with agents like warfarin or SSRIs (Selective Serotonin Reuptake Inhibitors) enhances the officially documented risk of bleeding complications.
  • Antihypertensives and Diuretics: Lormed can officially reduce the therapeutic efficacy of Diuretics, ACE Inhibitors, and ARBs (Angiotensin II Receptor Blockers).
  • Lithium and Methotrexate: Lormed reduces the renal excretion of both Lithium and Methotrexate, which is documented to increase their plasma concentrations and risk of toxicity.

Substance-Specific Caution

The consumption of alcohol is officially documented to increase the risk of gastrointestinal bleeding when administered concurrently with Lormed. Interaction risks associated with renal function are officially noted as being more significant in elderly patients.

Mechanism of Action

How Lormed Works

Receptor and Enzyme Target Engagement

Lormed works by selectively connecting with specific receptor or enzyme targets located within key regulatory pathways. This targeted binding is the precise pharmacodynamic action that initiates the drug's effect and modulates activity in systems where particular transmitters or mediators dominate.

Modulation of Signal Transduction Cascades

Following this initial engagement, Lormed enters well-defined signal transduction cascades, either suppressing or initiating molecular steps that control the flow of information inside target cells. This action is relevant in systems requiring targeted pathway adjustment and modifies early molecular steps that affect downstream physiological processes.

Mechanistic Activity and Regulation

The overall mechanism of Lormed is to modulate activity within pathways associated with elevated physiological activity. By influencing these core mechanisms and reducing the activity of excessive mediators, this activity alters signaling dynamics, resulting in a change toward a lower level of activity within targeted pathways, which results in the intended modulation of physiological processes.

Dosage and Administration Information

Official Administration Guidelines for Lormed

Lormed must be used strictly as directed by the prescribing healthcare provider. The official instructions for use, as outlined in regulatory documents, define the correct procedural steps for administration, dosing, and managing missed doses.

Administration Scope Official Regulatory Instruction
Route of Administration Oral. The tablet must be swallowed whole with a glass of water.
Preparation Requirements Tablets must not be chewed, crushed, or broken before swallowing.
Dosing Schedule The dose and duration are strictly as advised by the doctor. The prescribed amount should not be exceeded.
Timing in Relation to Meals Can be taken with or without food, but it is recommended to take it at a fixed time each day for optimal use.
Age-Group Rules Not generally recommended for use in children below 16 years of age.

Procedural Structure and Missed Doses

The full course of treatment must be completed exactly as instructed by the doctor, even if the user experiences relief early.

Handling Missed Doses:

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped completely, and the regular dosing schedule should be resumed. Do not take a double dose to compensate for the one that was missed.

This procedural structure ensures consistent delivery of the medicine as designed in the therapeutic regimen defined in official labeling. The administration rules provide clear instructions on how to take the medicine correctly and safely adhere to the prescribed frequency.

Recent Clinical Evidence

Research evidence / Overview of studies for Lormed

The clinical evaluation of Lormed (meloxicam) is based on formal research, primarily utilizing randomized controlled trials (RCTs) and systematic reviews, as required by regulatory bodies. Research for Lormed was studied for use in exploring patient-reported outcomes related to physical discomfort and functional limitations in specific populations. The information provided here strictly focuses on the research structure and the reported observations, avoiding clinical guidance or therapeutic advice.


Evidence for Use in Osteoarthritis (OA)

Research exploring Lormed's role in Osteoarthritis involves short- and intermediate-term randomized controlled trials (RCTs). These studies were applied in populations of adults diagnosed with OA, commonly affecting the knee or hip joints. Researchers examined outcomes related to physical discomfort and daily functioning using validated tools, such as the WOMAC index. Trial reports documented that the observed measurements in these outcomes were consistent with the expected patterns in this research context. However, the existing controlled evidence mainly provides insight into short-term symptomatic changes.


Evidence for Use in Adult Rheumatoid Arthritis (RA)

For adults with Rheumatoid Arthritis, evidence was derived from short-term RCTs, often conducted during periods of increased symptom activity. Studies monitored symptomatic outcomes using recognized response criteria, such as the ACR 20. A key limitation of the existing research is its focus entirely on the study of symptom patterns and the monitoring of inflammatory manifestations. The evidence structure does not contain studies designed to evaluate whether the medicine is associated with disease modification or the prevention of long-term joint damage.


Evidence for Use in Juvenile Idiopathic Arthritis (JIA)

Research evaluating Lormed for Juvenile Idiopathic Arthritis (JIA) was primarily structured as active-controlled randomized trials in children aged 2 to 16 years. Evidence for this special population is constrained by smaller sample sizes and a reliance on comparative data. Certainty remains lower compared to adult indications, and comparative evidence is lacking for certain subgroups.


What is Still Uncertain About Lormed's Research Base

The research base, while substantial for the study of symptoms in major arthritic conditions, includes several acknowledged research gaps. One major uncertainty is the limited information for long-term outcomes regarding the functional maintenance of joints. Additionally, data for certain groups remain insufficient. The research provides insight into short-term changes in symptoms, but the findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Lormed (FAQ)

Q: Is Lormed considered a narcotic or controlled substance by regulatory agencies?

Lormed is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

According to the scheduling and classification systems of major regulatory bodies, this drug is not considered a narcotic or a federally controlled substance.

Q: What is the main difference between Lormed and a similar drug like [Similar Drug Name]?

The official product information highlights Lormed's long elimination half-life, which describes how long the drug remains in the body.

This pharmacokinetic characteristic supports the medicine being taken once per day. This can differentiate it from other treatments in the same class that may require more frequent dosing.

Q: Why is Lormed prescribed for [Specific Condition] if it is also used for [Other Condition]?

Lormed is indicated for the treatment of inflammatory symptoms across several chronic conditions.

According to regulatory documents, this includes relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis (JIA) in children 2 years and older. The medicine's mechanism of action is broadly designed to modulate the inflammation common to these conditions.

Q: Do clinical studies suggest Lormed is generally effective for its intended purpose?

Studies that support Lormed's regulatory approval focused on its effect on signs and symptoms of inflammation.

Controlled clinical trials demonstrated efficacy in reducing pain and inflammation associated with its indicated conditions. It is important to remember that these findings describe group results, and individual experiences may vary.

Q: How quickly does Lormed typically start working after the first dose?

The speed at which Lormed is absorbed into the bloodstream can indicate when the initial effects may begin.

Official pharmacokinetic data shows that peak concentrations in the blood plasma are generally achieved approximately four to five hours after the medicine is taken orally.

Q: What is the expected timeline for a patient to feel the full benefit of Lormed?

Since Lormed is used to treat chronic inflammation, it can take time for the full anti-inflammatory effect to be achieved.

Clinical studies indicate that steady-state concentrations—the consistent level in the bloodstream needed for full effect—are typically reached by day five of consistent daily dosing.

Q: Are there any major food or drink interactions listed for Lormed?

Official administration guidelines state that the oral tablet form of Lormed can be taken without regard to food, meaning you can take it with or without a meal.

However, regulatory warnings note that consuming alcohol while using the medicine may increase the risk of serious gastrointestinal bleeding.

Q: Does the evidence suggest Lormed is a long-term treatment or short-term only?

Lormed is used to manage chronic conditions, but official documentation carries warnings related to the duration of use.

Regulatory advisories state that the drug should be used at the lowest effective dose for the shortest duration necessary, according to documented safety principles. This is intended to minimize the potential risk of cardiovascular and gastrointestinal adverse events.

Q: Is it normal to feel [General Sensation] when first starting Lormed?

According to official adverse event reports, some patients may experience gastrointestinal symptoms when taking Lormed.

These common side effects include occurrences of diarrhea, nausea, and indigestion (dyspepsia). Information regarding side effects should be reviewed with a healthcare professional.

Q: What kind of research has been done on Lormed's long-term safety profile?

The medicine's safety profile, particularly for serious events, is informed by both long-term clinical trial data and postmarketing surveillance.

Official warnings highlight that the risk of serious cardiovascular and gastrointestinal events increases with the duration of use. Current research generally focuses on symptomatic relief, and data regarding very long-term functional outcomes remain limited.

Q: Why are certain groups of people restricted from using Lormed?

Lormed is strictly restricted, or contraindicated, in certain populations to prevent the risk of documented harm.

For example, the medicine is strictly contraindicated for individuals with a known hypersensitivity to the drug or by patients receiving pain management immediately before or after coronary artery bypass graft (CABG) surgery. These prohibitions are based on documented safety risks identified in regulatory review.

Q: What are the official recommendations regarding alcohol consumption while using Lormed?

Official documentation advises caution regarding alcohol consumption while using this medicine.

Concomitant use with alcohol may substantially increase the risk of serious adverse events, specifically gastrointestinal bleeding and ulceration.

Q: Are there any genetic factors that official sources indicate may affect Lormed's efficacy?

Official clinical pharmacology information states that Lormed is processed in the body by specific liver enzymes, primarily CYP2C9 and CYP3A4.

Differences in these enzyme activities, which can be influenced by genetic factors, may contribute to individual variability in how the drug is exposed and eliminated from the body.

Q: What are the official guidelines for stopping Lormed therapy?

Official guidelines do not provide specific step-by-step instructions for stopping Lormed in patients with chronic conditions.

Official documents include the recommendation for using the lowest effective dose for the shortest possible duration to minimize risk. Any changes to a chronic treatment regimen must be managed by the patient’s prescribing healthcare professional.

Q: What does 'contraindication' mean in the context of Lormed's usage?

A contraindication is a regulatory term used to define specific conditions or situations in which a medication should not be used.

For Lormed, these are situations in which the use of the medicine is restricted or prohibited because the risk of using it is documented to be significantly higher than any potential benefit.

Q: Are there any documented interactions between Lormed and common vitamins or herbal supplements?

The official label focuses on drug-drug interactions, particularly those that affect blood clotting (hemostasis).

Warnings regarding these blood-clotting effects apply generally to any agents, including certain herbal supplements, that may interfere with this process. It is generally required that all supplements taken be disclosed to the prescribing healthcare professional.

Q: What is the purpose of the black box warning (if applicable) mentioned for Lormed?

The Boxed Warning is a stringent regulatory requirement used to highlight two serious and potentially life-threatening risks.

For Lormed, these risks are serious cardiovascular thrombotic events (such as heart attack and stroke) and severe gastrointestinal adverse events (such as bleeding and perforation).

Q: Does Lormed interact with caffeine or other common stimulants?

Official labels are primarily focused on documenting clinically significant drug-drug and drug-food interactions.

While specific warnings for non-alcoholic drinks such as caffeine or common stimulants are not typically listed as major interactions, information regarding all concurrent medication and supplements should be reviewed by a healthcare professional.

Q: What is the definition of 'serious adverse event' as it relates to Lormed?

A serious adverse event is a regulatory term describing any undesirable medical event that results in death, is immediately life-threatening, requires inpatient hospitalization, or results in persistent or significant disability.

The purpose of this classification is to ensure these high-risk events are specifically tracked and reported.

Q: Does Lormed have any known photosensitivity or sun exposure warnings?

Official adverse event documentation notes that increased sensitivity of the skin to sunlight, known as photosensitivity, is listed as an uncommon adverse reaction to Lormed.

Information regarding adverse events, including skin reactions, should be reviewed with a healthcare professional.

Q: Can Lormed cause weight changes (gain or loss) based on available reports?

Official adverse event reports indicate that changes in body weight (either increase or decrease) are listed as a potential, though infrequent, adverse reaction.

Furthermore, fluid retention (edema) is listed as a common effect, which may lead to temporary weight gain.

Q: Can Lormed affect mood or cause psychological side effects?

Rare adverse reactions affecting the central nervous system are listed in official documents.

These effects may include disturbances such as abnormal dreaming, anxiety, and nervousness. Information regarding adverse events, including changes in mood or behavior, should be reviewed with a healthcare professional.

How should Lormed be stored and disposed of?

Official Storage and Disposal Requirements for Lormed

The required storage conditions for Lormed are defined by regulatory labeling to ensure product quality and efficacy. The medication must be protected from high temperatures, with official instructions mandating storage below 30 C.

Mandatory Environmental Controls

Control Area Requirement
Temperature Store below 30 C and protect from heat.
Protection Protected from direct sunlight and moisture.

Disposal and Safety

Official regulatory documents require that Lormed be stored safely by being kept away from children and pets. For unused or expired medicine, disposal must be conducted properly. This means following appropriate pharmaceutical waste instructions to avoid discarding the product in household trash or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lormed found in:

A-Z Index: